Published in J Clin Immunol on April 08, 2009
Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int J Oncol (2011) 0.79
MICA polymorphisms and cancer risk: a meta-analysis. Int J Clin Exp Med (2015) 0.78
Association of MICA gene polymorphisms with liver fibrosis in schistosomiasis patients in the Dongting Lake region. Braz J Med Biol Res (2012) 0.77
MICA*A4 protects against ulcerative colitis, whereas MICA*A5.1 is associated with abscess formation and age of onset. Clin Exp Immunol (2016) 0.75
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 6.95
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 4.93
A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1994) 3.33
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol (2002) 2.72
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol (2001) 2.43
Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics (2001) 2.43
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. Proc Natl Acad Sci U S A (1997) 2.10
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005) 1.54
Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison's disease. J Clin Endocrinol Metab (1999) 1.45
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res (2006) 1.39
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A (2005) 1.36
Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol (2007) 1.32
The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant (2007) 1.19
In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS One (2007) 1.07
MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. Tissue Antigens (2001) 1.05
Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol (2007) 1.05
Typing for all known MICA alleles by group-specific PCR and SSOP. Hum Immunol (2001) 1.04
Nucleotide sequence of the human MHC class I MICA gene. Immunogenetics (1996) 1.02
Human gamma delta T cells: candidates for the development of immunotherapeutic strategies. Immunol Res (2007) 1.01
Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother (2007) 1.00
Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity. J Biol Chem (2007) 0.98
Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther (2006) 0.97
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res (2005) 0.97
NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann N Y Acad Sci (2007) 0.88
Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res (2007) 0.85
Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab (2006) 0.84
The increase of MICA gene A9 allele associated with gastric cancer and less schirrous change. Br J Cancer (2004) 0.79
Linkage disequilibria between HLA-B, C1_4_1, MICA and MICB. Tissue Antigens (2001) 0.77
Organization and evolution of the class I gene family in the major histocompatibility complex of the C57BL/10 mouse. Nature (1984) 4.22
The structure of a mutant H-2 gene suggests that the generation of polymorphism in H-2 genes may occur by gene conversion-like events. Nature (1983) 3.99
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Gender differences in long-term survival of patients with colorectal cancer. Br J Surg (2001) 3.18
Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med (1998) 2.87
A potential donor gene for the bm1 gene conversion event in the C57BL mouse. Nature (1984) 2.18
A nonpolymorphic class I gene in the murine major histocompatibility complex. Cell (1984) 2.12
A genome-wide search for linkage to asthma. German Asthma Genetics Group. Genomics (1999) 2.00
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Isolation and characterization of a human collagen alpha 1(I)-like gene from a cosmid library. Nucleic Acids Res (1982) 1.94
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Analysis of HL-A incompatibility in human renal transplants. Tissue Antigens (1971) 1.89
Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol (2000) 1.85
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens (1992) 1.58
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Interaction between Kb and Q4 gene sequences generates the Kbm6 mutation. Mol Cell Biol (1986) 1.50
Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol (1995) 1.50
Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol (1997) 1.42
A deletion in the second exon of an HLA-DRB1 allele found in a DR2-negative narcolepsy patient. Hum Immunol (1993) 1.41
Purification and characterization of cloacin DF13 receptor from Enterobacter cloacae and its interaction with cloacin DF13 in vitro. J Bacteriol (1979) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Routine molecular genotyping of HLA-B27 in spondyloarthropathies overcomes the obstacles of serological typing and reveals an increased B *2702 frequency in ankylosing spondylitis. J Rheumatol (1997) 1.39
Genetics of four new HL-A specificities in the Caucasian and Negro populations. Transplant Proc (1971) 1.38
Duplicated gene pairs and alleles of class I genes in the Qa2 region of the murine major histocompatibility complex: a comparison. EMBO J (1985) 1.36
Nomenclature for factors of the HLA system, 1995. Tissue Antigens (1995) 1.34
Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J (1991) 1.33
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut (2005) 1.30
Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med (1991) 1.26
Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol (1999) 1.26
Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease. Clin Exp Immunol (2004) 1.23
Nomenclature for factors of the HLA system, 2000. Tissue Antigens (2001) 1.21
Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur J Immunol (1991) 1.20
Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations. Immunobiology (1985) 1.20
Nomenclature for factors of the HLA system, 1994. Tissue Antigens (1994) 1.19
Nomenclature for factors of the HLA system, 1996. Tissue Antigens (1997) 1.18
Nomenclature for factors of the HLA system, 1995. Hum Immunol (1995) 1.16
Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection. Transplantation (1993) 1.11
Downregulation of tumor necrosis factor expression in the human Mono-Mac-6 cell line by lipopolysaccharide. J Leukoc Biol (1989) 1.08
Heterogeneity of human serum amyloid A protein. Five different variants from one individual demonstrated by cDNA sequence analysis. Biochem J (1990) 1.08
Nomenclature for factors of the HLA system, 2000. Eur J Immunogenet (2001) 1.08
Biosynthesis of complement C4 messenger RNA in normal human kidney. Nephron (1989) 1.06
Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol (1987) 1.06
MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. Tissue Antigens (2001) 1.05
Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol (1998) 1.05
Putting a hold on "HLA-H'. The WHO Nomenclature Committee for Factors of the HLA System. Nat Genet (1997) 1.05
Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. Cytokine (1990) 1.05
Joint report of the Second International Workshop on Canine Immunogenetics. Transplant Proc (1976) 1.05
Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod (2006) 1.03
Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Diabetologia (1999) 1.03
A 3' UTR transition within DEFB1 is associated with chronic and aggressive periodontitis. Genes Immun (2009) 1.03
The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol (1992) 1.01
Nomenclature for factors of the HLA system, 1990. Hum Immunol (1991) 1.01
Immunogenetics of rheumatoid arthritis in Israel. Tissue Antigens (1986) 0.99
An update to HLA nomenclature, 2010. Bone Marrow Transplant (2010) 0.96
Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol (1999) 0.96
Lack of class I H-2 antigens in cells transformed by radiation leukemia virus is associated with methylation and rearrangement of H-2 DNA. Proc Natl Acad Sci U S A (1986) 0.96
MICA sequences 2000. Immunogenetics (2001) 0.95
Segregation analysis of HL-A antigens and haplotypes in 50 families of patients with coeliac disease. Transplant Proc (1973) 0.94
Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum (1996) 0.94
A comprehensive search for segregation distortion in HLA. Hum Immunol (1987) 0.94
Nomenclature for factors of the HLA system, 1991. Hum Immunol (1992) 0.93
LST1: a gene with extensive alternative splicing and immunomodulatory function. J Immunol (2000) 0.92
Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol (2000) 0.92
Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion (2004) 0.92
Early-onset pauciarticular juvenile chronic arthritis is associated with a mutation in the Y-box of the HLA-DQA1 promoter. Tissue Antigens (1995) 0.92
Th1- and Th2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. Mol Hum Reprod (2002) 0.91
Immunoprinting: various genes are associated with increased risk to develop rheumatoid arthritis in different groups of adult patients. J Mol Med (Berl) (1995) 0.91
Nonradioactive HLA class II typing using polymerase chain reaction and digoxigenin-11-2'-3'-dideoxy-uridinetriphosphate-labeled oligonucleotide probes. Hum Immunol (1991) 0.91
Linkage group HL-A-MLC-BF (properdin factor B). The site of the Bf locus at the immunogenetic linkage group on chromosome 6. Humangenetik (1975) 0.91
Nomenclature for factors of the HLA System, 1998. Hum Immunol (1999) 0.91
Deduction of 2140 HL-A haplotypes and segregation analysis in 535 families. Transplant Proc (1973) 0.91
Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum (1993) 0.91
Sequence of a putative human housekeeping gene (HK33) localized on chromosome 1. Gene (1994) 0.91
Susceptible and protective major histocompatibility complex class II alleles in early-onset pauciarticular juvenile chronic arthritis. Hum Immunol (1994) 0.91
Cloning and genomic characterization of LST1: a new gene in the human TNF region. Immunogenetics (1995) 0.90
Sequence of the mouse Q4 class I gene and characterization of the gene product. Immunogenetics (1988) 0.89
Genetics of insulin dependent diabetes mellitus in Israel: population and family study. Hum Immunol (1981) 0.89
Allelic variation in HLA-B and HLA-C sequences and the evolution of the HLA-B alleles. Immunogenetics (1989) 0.89
HLA-G: expression in human keratinocytes in vitro and in human skin in vivo. Eur J Immunol (1994) 0.89
DR2-negative narcolepsy. Lancet (1986) 0.89
Human interleukin-1 receptor antagonist is expressed in liver. FEBS Lett (1992) 0.88
Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding. J Exp Med (1992) 0.88
Murine leukemia virus sequences are encoded in the murine major histocompatibility complex. Proc Natl Acad Sci U S A (1984) 0.88
Nomenclature for factors of the HLA system, 2000. Hum Immunol (2001) 0.88
Localization of the genes for tumor necrosis factor and lymphotoxin between the HLA class I and III regions by field inversion gel electrophoresis. Immunogenetics (1988) 0.88
Cloning of the 1.4-kb mRNA species of human complement factor H reveals a novel member of the short consensus repeat family related to the carboxy terminal of the classical 150-kDa molecule. J Immunol (1991) 0.87
Nomenclature for factors of the HLA System, 1996. Hum Immunol (1997) 0.86
Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB-MHC haplotypes. Immunogenetics (1993) 0.86
Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res (2001) 0.86
HLA-DP/DR interaction in early onset pauciarticular juvenile chronic arthritis. Immunogenetics (1993) 0.86
High serum IgE concentrations: association with HLA-DR and markers on chromosome 5q31 and chromosome 11q13. J Allergy Clin Immunol (1997) 0.86
Nomenclature for factors of the HLA system, 1996. Eur J Immunogenet (1997) 0.85
In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology (1998) 0.85
Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet (2007) 0.85